<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drugs for discoid lupus erythematosus - Jessop, S - 2017 | Cochrane Library</title> <meta content="Drugs for discoid lupus erythematosus - Jessop, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002954.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drugs for discoid lupus erythematosus - Jessop, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002954.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002954.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Drugs for discoid lupus erythematosus" name="citation_title"/> <meta content="Sue Jessop" name="citation_author"/> <meta content="University of Cape Town Groote Schuur Hospital" name="citation_author_institution"/> <meta content="susan.jessop@uct.ac.za" name="citation_author_email"/> <meta content="David A Whitelaw" name="citation_author"/> <meta content="University of Stellenbosch" name="citation_author_institution"/> <meta content="Matthew J Grainge" name="citation_author"/> <meta content="School of Medicine" name="citation_author_institution"/> <meta content="Prativa Jayasekera" name="citation_author"/> <meta content="Broadgreen Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD002954.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002954.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002954.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002954.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acitretin [adverse effects, therapeutic use]; Albuterol [therapeutic use]; Calcineurin Inhibitors [therapeutic use]; Dermatologic Agents [adverse effects, *therapeutic use]; Fluocinonide [therapeutic use]; Hydrocortisone [therapeutic use]; Hydroxychloroquine [therapeutic use]; Lupus Erythematosus, Discoid [*drug therapy]; Randomized Controlled Trials as Topic; Tacrolimus [analogs &amp; derivatives, therapeutic use]; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002954.pub3&amp;doi=10.1002/14651858.CD002954.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002954\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002954\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","th","hr","pl","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002954.pub3",title:"Drugs for discoid lupus erythematosus",firstPublishedDate:"May 5, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002954.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002954.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002954.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002954.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002954.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002954.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002954.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002954.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002954.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002954.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7748 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002954.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0102"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/appendices#CD002954-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/table_n/CD002954StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/table_n/CD002954StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drugs for discoid lupus erythematosus</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#CD002954-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sue Jessop</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#CD002954-cr-0003">David A Whitelaw</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#CD002954-cr-0004">Matthew J Grainge</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information#CD002954-cr-0005">Prativa Jayasekera</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information/en#CD002954-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002954.pub3">https://doi.org/10.1002/14651858.CD002954.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002954-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002954-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002954-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002954-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD002954-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002954-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002954-abs-0001" lang="en"> <section id="CD002954-sec-0001"> <h3 class="title" id="CD002954-sec-0001">Background</h3> <p>Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most appropriate treatment for an individual with DLE. </p> </section> <section id="CD002954-sec-0002"> <h3 class="title" id="CD002954-sec-0002">Objectives</h3> <p>To assess the effects of drugs for discoid lupus erythematosus.</p> </section> <section id="CD002954-sec-0003"> <h3 class="title" id="CD002954-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to 22 September 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials databases, and checked the reference lists of included studies for further references to relevant trials. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about unpublished trials. </p> </section> <section id="CD002954-sec-0004"> <h3 class="title" id="CD002954-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) of drugs to treat people with DLE in any population group and of either gender. Comparisons included any drug used for DLE against either another drug or against placebo cream. We excluded laser treatment, surgery, phototherapy, other forms of physical therapy, and photoprotection as we did not consider them drug treatments. </p> </section> <section id="CD002954-sec-0005"> <h3 class="title" id="CD002954-sec-0005">Data collection and analysis</h3> <p>At least two reviewers independently extracted data onto a data extraction sheet, resolving disagreements by discussion. We used standard methods to assess risk of bias, as expected by Cochrane. </p> </section> <section id="CD002954-sec-0006"> <h3 class="title" id="CD002954-sec-0006">Main results</h3> <p>Five trials involving 197 participants were included. Three new trials were included in this update. None of the five trials were of high quality. </p> <p>'Risk of bias' assessments identified potential sources of bias in each study. One study used an inappropriate randomisation method, and incomplete outcome data were a concern in another as 15 people did not complete the trial. We found most of the trials to be at low risk in terms of blinding, but three of the five did not describe allocation concealment. </p> <p>The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of life measures). </p> <p>One study of fluocinonide cream 0.05% (potent steroid) compared with hydrocortisone cream 1% (low‐potency steroid) in 78 people reported complete resolution of skin lesions in 27% (10/37) of participants in the fluocinonide cream group and in 10% (4/41) in the hydrocortisone group, giving a 17% absolute benefit in favour of fluocinonide (risk ratio (RR) 2.77, 95% CI 0.95 to 8.08, 1 study, n = 78, low‐quality evidence). The other primary outcome measures were not reported. Adverse events did not require discontinuation of the drug. Skin irritation occurred in three people using hydrocortisone, and one person developed acne. Burning occurred in two people using fluocinonide (moderate‐quality evidence). </p> <p>A comparative trial of two oral agents, acitretin (50 mg daily) and hydroxychloroquine (400 mg daily), reported two of the outcomes of interest: complete resolution was seen in 13 of 28 participants (46%) on acitretin and 15 of 30 participants (50%) on hydoxychloroquine (RR 0.93, 95% CI 0.54 to 1.59, 1 study, n = 58, low‐quality evidence). Clearing of erythema in at least 50% of lesions was reported in 10 of 24 participants (42%) on acitretin and 17 of 25 (68%) on hydroxychloroquine (RR 0.61, 95% CI 0.36 to 1.06, 1 study, n = 49, low‐quality evidence). This comparison did not assess improvement in patient satisfaction/quality of life measures. Participants taking acitretin showed a small increase in serum triglyceride, not sufficient to require withdrawal of the drug. The main adverse effects were dry lips (93% of the acitretin group and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin group and 17% of the hydroxychloroquine group). Four participants on acitretin withdrew due to gastrointestinal events or dry lips (moderate‐quality evidence). </p> <p>One trial randomised 10 people with DLE to apply a calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone 17‐valerate 0.1% cream, for eight weeks. The study reported none of the primary outcome measures, nor did it present data on adverse events. </p> <p>A trial of calcineurin inhibitors compared tacrolimus cream 0.1% with placebo (vehicle) over 12 weeks in 14 people, but reported none of our primary outcome measures. In the tacrolimus group, five participants complained of slight burning and itching, and for one participant, a herpes simplex infection was reactivated (moderate‐quality evidence). </p> <p>Topical R‐salbutamol 0.5% cream was compared with placebo (vehicle) over eight weeks in one trial of 37 people with DLE. There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life. None of the primary outcome measures were reported. Changes in erythema did not show benefit of salbutamol over placebo, but we could not obtain from the trial report the number of participants with clearing of erythema in at least 50% of lesions. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by nine participants). None of the adverse events were considered serious (moderate‐quality evidence). </p> </section> <section id="CD002954-sec-0007"> <h3 class="title" id="CD002954-sec-0007">Authors' conclusions</h3> <p>Fluocinonide cream may be more effective than hydrocortisone in clearing DLE skin lesions. Hydroxychloroquine and acitretin appear to be of equal efficacy in terms of complete resolution, although adverse effects might be more frequent with acitretin, and clearing of erythema in at least 50% of lesions occurred less often in participants applying acitretin. Moderate‐quality evidence found adverse events were minor on the whole. There is not enough reliable evidence about other drugs used to treat DLE. Overall, the quality of the trials and levels of uncertainty were such that there is a need for further trials of sufficient duration comparing, in particular, topical steroids with other agents. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002954-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002954-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002954-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002954-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002954-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002954-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002954-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD002954-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002954-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002954-abs-0004" lang="en"> <h3>Drugs for discoid lupus erythematosus</h3> <p><b>Background</b> </p> <p>Discoid lupus erythematosus (DLE) is a form of skin inflammation which occurs particularly on sun‐exposed skin and can cause scarring. All forms of cutaneous lupus erythematosus are most common in women of childbearing age, which is important because some treatments, including thalidomide and acitretin, can cause birth defects, and hydroxychloroquine may cause damage to the eye or ear. As the chronic nature and scarring of DLE can have psychological impact, and some treatments may produce serious adverse effects, we felt it was important to combat uncertainty and identify the best and safest treatment. The evidence is current to September 2016. </p> <p><b>Review question</b> </p> <p>We aimed to identify the best treatment for people with DLE, to reduce the risk of scarring and possible psychological effects. We searched for all possible drug treatments, including topical agents (steroids and pimecrolimus or tacrolimus) and oral agents, such as hydroxychloroquine, retinoids, methotrexate, azathioprine, lenalidomide, and biological agents. Potentially, any of these interventions could have been compared with placebo or with any other intervention. We excluded surgery, laser, photoprotection, phototherapy, and other forms of physical therapy as we did not consider them drug treatments. We hoped to find evidence for effective treatment, without serious adverse effects. </p> <p><b>Study characteristics</b> </p> <p>We identified five studies, involving 197 people (aged between 17 and 82). Participants were recruited from Europe, Scandinavia, Iran, and the United States. Most of the skin lesions were recorded on the face, ear, and scalp. The duration of disease ranged from one month to 16 years. Treatments included steroid creams of different potencies (fluocinonide and betamethasone cream, both potent steroids; and hydrocortisone, a low‐potency steroid); oral hydroxychloroquine; oral acitretin; tacrolimus cream; pimecrolimus cream; and salbutamol cream. The tacrolimus and salbutamol trials used placebo in the control arm. </p> <p><b>Key results</b> </p> <p>In a trial involving 78 participants, fluocinonide cream 0.05% appeared nearly three times as effective as hydrocortisone cream 1% in terms of complete clearing of the DLE (27% versus 10%). The percentage of people who had a reduction in the redness of at least 50% of their sores was not reported, nor was patient satisfaction. Skin irritation occurred in three people using hydrocortisone and one person developed acne; burning occurred in two people using fluocinonide. Adverse events did not stop any participants continuing to apply the creams. </p> <p>Hydroxychloroquine 400 mg and acitretin 50 mg appear to work equally well in terms of complete resolution (50% versus 46%, respectively). Marked improvement in redness may be less in the acitretin group (42% versus 68%), but neither drug has been compared with placebo. Patient satisfaction was not measured. Adverse events, more common in the acitretin group, were reported as minor, although four people stopped treatment due to dry lips and gastrointestinal symptoms. </p> <p>Pimecrolimus cream 1% (an anti‐inflammatory cream) was compared with betamethasone (steroid) 0.1% cream in a small 8‐week study involving 10 people, but none of the review primary outcomes were reported; nor were adverse effects. </p> <p>A longer study using a similar type of cream, tacrolimus 0.1%, compared with placebo did not report the primary outcomes. Slight burning and itching was reported in five participants applying tacrolimus, and a herpes simplex infection came back in one participant. A few people reported burning or irritation after the use of tacrolimus cream, but not sufficient to cause withdrawal. </p> <p>R‐salbutamol 0.5% topical cream was compared with placebo cream in a trial of 37 people, but the primary outcomes of this review were not reported. There were only minor adverse events reported in each group: 15 in the placebo group and 24 in the salbutamol group. </p> <p><b>Quality of the evidence</b> </p> <p>For our primary outcome of clearing or excellent improvement, we had low‐quality evidence for fluocinonide 0.05% compared with hydrocortisone 1% as the only study assessing this comparison contained a high number of dropouts; while for acitretin (50 mg) compared with hydroxychloroquine (400 mg), for our primary outcomes of reduction in erythema and complete resolution we rated the quality of evidence as low, as the study contained a small number of people and differences between the groups in the number of people who had forms of lupus other than DLE. Overall, moderate‐quality evidence was found for adverse events. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002954-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002954-sec-0102"></div> <h3 class="title" id="CD002954-sec-0103">Implications for practice</h3> <section id="CD002954-sec-0103"> <p> <ol id="CD002954-list-0009"> <li> <p>There is currently insufficient evidence to guide clinicians in the treatment of severe DLE. </p> </li> <li> <p>Potent steroid cream (fluocinonide) appears to be more effective than low‐potency steroid cream (hydrocortisone) in the treatment of discoid lupus erythematosus, although the potent steroid was effective in only about a quarter of the people treated and the low‐potency steroid in about 10%. </p> </li> <li> <p>Both hydroxychloroquine and acitretin are associated with marked improvement or clearing in about half of all people treated, but neither drug has been tested against placebo in a randomised clinical trial. </p> </li> <li> <p>At present there is no reliable evidence to support the use of other specific treatments for discoid lupus erythematosus. This should not be seen as evidence that current treatment is ineffective but rather that evidence of effectiveness is lacking. Notably, there have been several large multicentre trials of newer biological agents (<a href="./references#CD002954-bbs2-0018" title="ManziS , Sánchez‐GuerreroJ , MerrillJT , FurieR , GladmanD , NavarraSV , et al. Effects of belimumab, a B lymphocyte stimulator‐specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases2012;71(11):1833‐8. [PUBMED: 22550315] ">Manzi 2012</a>, <a href="./references#CD002954-bbs2-0019" title="MerrillJT , Burgos‐VargasR , WesthovensR , ChalmersA , D'CruzD , WallaceDJ , et al. The efficacy and safety of abatacept in patients with non‐life‐threatening manifestations of systemic lupus erythematosus: results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2010;62(10):3077‐87. [PUBMED: 20533545] ">Merrill 2010a</a>, <a href="./references#CD002954-bbs2-0021" title="MerrillJT , WallaceDJ , PetriM , KirouKA , YaoY , WhiteWI , et al. Safety profile and clinical activity of sifalimumab, a fully human anti‐interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double‐blind randomised study. Annals of the Rheumatic Diseases2011;70(11):1905‐13. [PUBMED: 21798883] ">Merrill 2011</a>, <a href="./references#CD002954-bbs2-0020" title="MerrillJT , NeuweltCM , WallaceDJ , ShanahanJC , LatinisKM , OatesJC , et al. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis and Rheumatism2010;62(1):222‐33. [PUBMED: 20039413] ">Merrill 2010b</a>, <a href="./references#CD002954-bbs2-0023" title="SzepietowskiJC , NilganuwongS , WozniackaA , KuhnA , NybergF , vanVollenhovenRF , et al. Phase I, randomized, double‐blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis and Rheumatism2013;65(10):2661‐71. [PUBMED: 23896980] ">Szepietowski 2013</a>), but unfortunately cutaneous subsets have not been reported separately, so we cannot reach any conclusion about possible benefits of biological agents in DLE. Trials investigating the use of topical biological agents have been registered but no data from such trials is available at present. </p> </li> <li> <p>The study in ‘<a href="./references#CD002954-bbs1-0003" title="">Studies awaiting classification</a>’ may alter the conclusions of the review once assessed. </p> </li> </ol> </p> </section> <h3 class="title" id="CD002954-sec-0104">Implications for research</h3> <section id="CD002954-sec-0104"> <p>A combination of small numbers, different outcome measures and short duration reduce the strength of most of these trials and the results need to be confirmed in larger trials. </p> <p>The early single lesion of DLE may respond well to potent steroid creams. One of the goals should be to prevent scarring as, once it occurs, it is largely irreversible. </p> <p>Well‐planned randomised controlled trials are needed to provide a guide to the treatment of discoid lupus erythematosus. Trials should not mix different types of lupus together and ideally the diagnosis should be confirmed with a skin biopsy. There is a need for trials comparing topical steroids with other agents. The outcome measures should be stated clearly and should include participants' views and information about scarring. If the CLASI scoring system is adopted widely, more consistent outcome measures may be obtained. If future trials were to include a core set of outcome measures, following the recent COUSIN initiative from the Cochrane Skin Group, there is a much greater likelihood of being able to pool results from multiple studies in future updates of this review. </p> <p>Also, the trials should be of sufficient duration to allow for seasonal variation and capture of relapses (suggested minimum of 9 months). Recurrence rate on and off treatment and occurrence of side‐effects should be documented. Priorities for further studies, involving larger numbers, are as follows. </p> <p> <ol id="CD002954-list-0010"> <li> <p>Potent topical steroid versus chloroquine or hydroxychloroquine (these antimalarials are cheap and widely available in many countries). </p> </li> <li> <p>Potent topical steroid versus oral retinoid (more expensive and can cause birth defects).</p> </li> <li> <p>Potent topical steroid versus methotrexate (cheap and available but possible liver and bone marrow toxicity, so needs careful monitoring). </p> </li> <li> <p>Potent topical steroid versus lenalidomide (similar to thalidomide, but possibly with a better safety profile). </p> </li> <li> <p>Potent topical steroids or chloroquine versus biological agents.</p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002954-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002954-sec-0029"></div> <div class="table" id="CD002954-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fluocinonide 0.05% compared with hydrocortisone 1%</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fluocinonide 0.05% compared with hydrocortisone 1% for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> not stated </p> <p><b>Intervention:</b> fluocinonide </p> <p><b>Comparison:</b> hydrocortisone </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>hydrocortisone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>fluocinonide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> <p>(after 6 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 100</p> <p>(9 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.77 (0.95 to 8.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of adverse events in this study was small and results were presented narratively. For hydrocortisone, 1 person developed acne and 3 experienced irritation. 2 patients who were assigned to fluocinonide experienced burning. There was no discontinuation in either group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk was the mean risk for the study population</p> <p><sup>1</sup>Downgraded by two levels due to imprecision and high risk of bias (incomplete outcome data).<br/> <sup>2</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002954-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> specialised lupus clinic </p> <p><b>Intervention:</b> acitretin </p> <p><b>Comparison:</b> hydroxychloroquine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>hydroxychloroquine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>acitretin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> <p>(after 8 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 100</p> <p>(27 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.54 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> <p>(after 8 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 100</p> <p>(25 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61 (0.36 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information on adverse events was presented narratively. 27 out of 28 participants receiving acitretin had at least one adverse event compared with 17 out of 30 patients treated with hydroxychloroquine. 4 people receiving acitretin discontinued treatment due to dry lips and gastrointestinal symptoms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk was the mean risk for the study population.</p> <p><sup>1</sup>Downgraded by two levels due to imprecision and high risk of bias (non‐comparable treatment arms).<br/> <sup>2</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002954-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1%</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1% for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> dermatology clinics </p> <p><b>Intervention:</b> pimecrolimus </p> <p><b>Comparison:</b> betamethasone </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> <p>(after 8 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a statistically significant reduction in the disease severity score in both treatment groups; however, clearing or improvement was not presented as a percentage and no comparative analyses were performed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD002954-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">R‐salbutamol 0.5% topical cream compared with placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>R‐salbutamol 0.5% topical cream compared with placebo for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> dermatology departments </p> <p><b>Intervention:</b> R‐salbutamol </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>While data on overall improvement were provided in the study, the number of participants with complete resolution in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> could not be obtained from the trial report. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>While data on erythema were provided in the study report, the number of participants with at least 50% reduction in erythema in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> could not be obtained from the trial report. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results for adverse events were presented narratively. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by 9 participants). None of the adverse events were considered serious. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002954-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tacrolimus 0.1% cream compared with placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% cream compared with placebo for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> dermatology departments </p> <p><b>Intervention:</b> tacrolimus </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants with DLE in either group in the study by <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> experienced complete clearing. Unable to GRADE due to 0 events in both groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results for erythema in the study by <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> were not reported separately. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results for adverse events were presented narratively. In the tacrolimus group, 5 participants complained of slight burning and itching, and in 1 person a herpes simplex infection was reactivated. There were no serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002954-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002954-sec-0030"></div> <section id="CD002954-sec-0031"> <h3 class="title" id="CD002954-sec-0031">Description of the condition</h3> <p>Discoid lupus erythematosus (DLE) is a chronic and common form of cutaneous lupus — a form of skin inflammation of unknown cause. It occurs particularly on sun‐exposed skin, such as the face, ears, and scalp, but occasionally is much more extensive, involving large areas of skin. Some people with DLE have associated disease in other parts of the body, but the majority of people with DLE are otherwise healthy. People with DLE are seen frequently in skin clinics throughout the world. </p> <p>There have been no accurate studies of the prevalence of DLE, although all forms of lupus erythematosus are particularly common in women of childbearing age. The diagnosis of DLE is usually made easily on clinical grounds, characteristic clinical findings being erythema (redness), follicular plugging (blocked and enlarged openings to hair follicles), pigmentary disturbances, telangiectasia (dilated capillaries), and atrophy (skin thinning). When the diagnosis is in doubt, a skin biopsy (microscopic examination) may be required to confirm the diagnosis (<a href="./references#CD002954-bbs2-0063" title="KuhnA , LandmannA . The classification and diagnosis of cutaneous lupus erythematosus. Journal of Autoimmunity2014;48‐49:14‐9. [PUBMED: 24486120] ">Kuhn 2014</a>). </p> <p>In an attempt to improve consistency in the reporting of clinical trials, the CLASI (Cutaneous Lupus Erythematosus Area and Severity Index) scoring system has been developed (<a href="./references#CD002954-bbs2-0039" title="AlbrechtJ , TaylorL , BerlinJA , DulayS , AngG , FakharzadehS , et al. The CLASI (Cutaneous Lupus Erythematosus disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. Journal of Investigative Dermatology2005;125(5):889‐94. [PUBMED: 16297185] ">Albrecht 2005</a>). The CLASI allows assessment of both active inflammation (erythema, scale, and hypertrophy) and damage (dyspigmentation, scarring, atrophy), in different body areas, but does not include a quality of life score. It has not been tested in different populations. </p> <p>Early effective treatment may lead to total clearing of the skin lesions, but failure of treatment results in permanent scarring. The depressed scars, hair loss, and pigmentary changes are often extremely disfiguring, particularly in darker‐skinned people. Permanent scarring is the rule if treatment is delayed or inadequate. Great emotional distress, social isolation, and difficulty obtaining work are problems frequently suffered by these patients. Involvement of the skin of the fingers and toes may markedly impair hand function and limit walking (<a href="./references#CD002954-bbs2-0086" title="VasquezR , WangD , TranQP , Adams‐HuetB , ChrenMM , CostnerMI , et al. A multicentre, cross‐sectional study on quality of life in patients with cutaneous lupus erythematosus. British Journal of Dermatology2013;168(1):145‐53. [PUBMED: 22708924] ">Vasquez 2013</a>). In addition, people with DLE are at risk of developing squamous cell carcinoma in the scarred areas (<a href="./references#CD002954-bbs2-0050" title="FernandesMS , GirishaBS , ViswanathanN , SripathiH , NoronhaTM . Discoid lupus erythematosus with squamous cell carcinoma: a case report and review of the literature in Indian patients. Lupus2015;24(14):1562‐6. [PUBMED: 26251401] ">Fernandes 2015</a>). </p> </section> <section id="CD002954-sec-0032"> <h3 class="title" id="CD002954-sec-0032">Description of the intervention</h3> <p>The anti‐malarial drug chloroquine is the traditional therapy for DLE (<a href="./references#CD002954-bbs2-0053" title="GoldmanL , ColeDP , PrestonRH . Chloroquine diphosphate in treatment of discoid lupus erythematosus. Journal of the American Medical Association1953;152(15):1428‐9. [PUBMED: 13061294] ">Goldman 1953</a>; <a href="./references#CD002954-bbs2-0041" title="BrodthagenH . Hydroxychloroquine (Plaquenil) in the treatment of lupus erythematosus. Acta Dermato‐venereologica1959;39:233‐7. [PUBMED: 13804646] ">Brodthagen 1959</a>; <a href="./references#CD002954-bbs2-0042" title="CallenJP . Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Archives of Dermatology1982;118(6):412‐6. [PUBMED: 7092253] ">Callen 1982</a>). It is cheap and readily available worldwide. Flare‐ups of systemic lupus were noted to occur with increased frequency after chloroquine was stopped (<a href="./references#CD002954-bbs2-0078" title="RothfieldNF , MarchC , MiescherP , McEwenC . Chronic discoid lupus erythematosus ‐ a study of 65 patients and 65 controls. New England Journal of Medicine1963;269:1155‐61. ">Rothfield 1963</a>). However, some people cannot tolerate the drug and it is known to fail in others. Other anti‐malarial agents have been used, sometimes in combination with chloroquine, but are not widely available (<a href="./references#CD002954-bbs2-0059" title="KierlandRR , BrunstingLA , O'LearyPA . Quinacrine hydrochloride (atabrine) in the treatment of lupus erythematosus. Archives of Dermatology and Syphilology1953;68(6):651‐9. [PUBMED: 13103808] ">Kierland 1953</a>; <a href="./references#CD002954-bbs2-0066" title="MaguireA . Amodiaquine hydrochloride in the treatment of chronic discoid lupus erythematosus. Lancet1962;1(7231):665‐7. [PUBMED: 14468396] ">Maguire 1962</a>; <a href="./references#CD002954-bbs2-0049" title="FeldmanR , SalomonD , SauratJH . The association of the two antimalarials chloroquine and quinacrine for treatment‐resistant chronic and subacute cutaneous lupus erythematosus. Dermatology1994;189(4):425‐7. [PUBMED: 7873836] ">Feldman 1994</a>). </p> <p>In recent years, hydroxychloroquine has been used in place of chloroquine in many countries, because ocular side‐effects were reported to be less frequent with hydroxychloroquine, but retinal toxicity has subsequently also been recognised with hydroxychloroquine (<a href="./references#CD002954-bbs2-0051" title="Geamanu PancaA , Popa‐CherecheanuA , MarinescuB , GeamănuCD , VoineaLM . Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. Journal of Medicine and Life2014;7(3):322‐326. [PUBMED: 25408748] ">Geamanu 2014</a>). The efficacy of the two forms of the drug is thought to be the same, but no trials exist to confirm this in DLE (<a href="./references#CD002954-bbs2-0062" title="KreuterA , GaifullinaR , TiggesC , KirschkeJ , AltmeyerP , GambichlerT . Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Archives of Dermatology2009;145(3):244‐8. [PUBMED: 19289751] ">Kreuter 2009</a>). In discussing the treatment of DLE in 1961, Prakken commented that: "This [lack of evidence] is illustrated by a survey of our literature on the treatment of chronic lupus erythematosus. Although many papers agree on their reports of favourable results, the value of our therapy remains doubtful because the influence of the placebo effect and the publications effect has not been eliminated" (<a href="./references#CD002954-bbs2-0073" title="PrakkenJR . Difficulty in judging the value of therapy. Observations in connection with reports on the treatment of chronic lupus erythematosus [Oorspronkelijke Stukken. Het moeilijke oordeel over de waarde van een therapie]. Nederlands Tijdschrift voor Geneeskunde1961;105:971‐6. [PUBMED: 13737707] ">Prakken 1961</a>). However, Rees felt that discoid lupus responded so dramatically to chloroquine that "double‐blind studies are not required" (<a href="./references#CD002954-bbs2-0075" title="ReesRB , MaibachHI . Chloroquine. A review of reactions and dermatologic indications. Archives of Dermatology1963;88:280‐9. [PUBMED: 14043620] ">Rees 1963</a>). In 1964, Kraak performed a literature search and concluded that available information was insufficient to evaluate the many therapies that are recommended: "The literature leaves room for the alarming assumption that none of the drugs might do any good" (<a href="./references#CD002954-bbs2-0061" title="KraakJH . Local treatment of chronic lupus erythematosus with triamcinolone injections [Lokale behandeling van chronische (lupus) erythematodes]. Nederlands Tijdschrift voor Geneeskunde1964;108:1305‐6. [PUBMED: 14177187] ">Kraak 1964</a>). His group performed a non‐randomised double‐blind trial comparing hydroxychloroquine with placebo (<a href="./references#CD002954-bbs2-0014" title="KraakJH , vanKetelW , PrakkenJR , VanZwetW . The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica1965;130:293‐305. [PUBMED: 14333636] ">Kraak 1965</a>). Spontaneous improvement or clearing occurred in some of their patients, particularly in the winter months (<a href="./references#CD002954-bbs2-0014" title="KraakJH , vanKetelW , PrakkenJR , VanZwetW . The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica1965;130:293‐305. [PUBMED: 14333636] ">Kraak 1965</a>). The group on chloroquine showed a greater tendency to improve (<a href="./references#CD002954-bbs2-0014" title="KraakJH , vanKetelW , PrakkenJR , VanZwetW . The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial. Dermatologica1965;130:293‐305. [PUBMED: 14333636] ">Kraak 1965</a>). Other workers have been so concerned about possible ocular side‐effects (thought to be very rare on current low dosage regimens) that chloroquine was excluded from their trial (<a href="./references#CD002954-bbs2-0065" title="MackeyJP , BarnesJ . Clofazimine in the treatment of discoid lupus erythematosus. British Journal of Dermatology1974;91(1):93‐6. [PUBMED: 4851057] ">Mackey 1974</a>). Smoking may reduce the efficacy of chloroquine in people with lupus: a recent review reports studies that demonstrate an inverse relationship between number of cigarettes smoked and chloroquine blood levels (<a href="./references#CD002954-bbs2-0044" title="ChassetF , FrancèsC , BareteS , AmouraZ , Arnaudl . Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta‐analysis of the literature. Journal of the American Academy of Dermatology2015;72(4):634‐9. [PUBMED: 25648824] ">Chasset 2015</a>). Unfortunately many of the other agents, reported anecdotally to be of value in discoid lupus erythematosus, have considerable potential side‐effects and some, such as thalidomide, may produce major malformations in the foetus if taken during pregnancy (<a href="./references#CD002954-bbs2-0046" title="Cortés‐HernándezJ , Torres‐SalidoM , Castro‐MarreroJ , Vilardell‐TarresM , Ordi‐RosJ . Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. British Journal of Dermatology2012;166(3):616‐23. [PUBMED: 21999437] ">Cortés‐Hernández 2012</a>; <a href="./references#CD002954-bbs2-0089" title="ZhouS , WangF , HsiehTC , WuJM , WuE . Thalidomide ‐ a notorious sedative to a wonder anticancer drug. Current Medicinal Chemistry2013;20(33):4102‐8. [PUBMED: 23931282] ">Zhou 2013</a>). </p> <p>Many other agents have been used to treat this condition (<a href="./references#CD002954-bbs2-0043" title="CallenJP . Management of antimalarial‐refractory cutaneous lupus erythematosus. Lupus1997;6(2):203‐8. [PUBMED: 9061669] ">Callen 1997</a>). Sunscreens and sun avoidance reduce flares of cutaneous lupus, but are not usually sufficient alone (<a href="./references#CD002954-bbs2-0015" title="KuhnA , GenschK , HaustM , MeuthAM , BoyerF , DupuyP , et al. Photoprotective effects of a broad‐spectrum sunscreen in ultraviolet‐induced cutaneous lupus erythematosus: a randomized, vehicle‐controlled, double‐blind study. Journal of the American Academy of Dermatology2011;64(1):37‐48. [PUBMED: 21167404] ">Kuhn 2011a</a>). Other possible treatments include dapsone (<a href="./references#CD002954-bbs2-0045" title="CoburnPR , ShusterS . Dapsone and discoid lupus erythematosus. British Journal of Dermatology1982;106(1):105‐6. [PUBMED: 7059497] ">Coburn 1982</a>; <a href="./references#CD002954-bbs2-0064" title="LindskovR , ReymannF . Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica1986;172(4):214‐7. [PUBMED: 3519302] ">Lindskov 1986</a>), topical and intralesional steroids (please note that the term 'steroid' has been used in this review in place of the term 'corticosteroid', although both terms have the same meaning) (<a href="./references#CD002954-bbs2-0057" title="JansenGT , DillahaCJ , HoneycuttWM . Discoid lupus erythematosus. Is systemic treatment necessary?. Archives of Dermatology1965;92(3):283‐5. [PUBMED: 11851251] ">Jansen 1965</a>; <a href="./references#CD002954-bbs2-0067" title="MarsdenCW . Fluocinolone acetonide 0.2 per cent cream ‐ a co‐operative clinical trial. British Journal of Dermatology1968;80(9):614‐7. [PUBMED: 4877599] ">Marsden 1968</a>; <a href="./references#CD002954-bbs2-0076" title="ReymanF . Treatment of discoid lupus erythematosus with betametasone‐valerate cream 1 percent. Dermatologica1974;149(2):65‐8. [PUBMED: 4615953] ">Reyman 1974</a>; <a href="./references#CD002954-bbs2-0082" title="SmithJF . Intralesional triamcinolone as an adjunct to antimalarial drugs in the treatment of chronic discoid lupus erythematosus. British Journal of Dermatology1962;74:350‐3. [PUBMED: 13989464] ">Smith 1986</a>), gold (<a href="./references#CD002954-bbs2-0047" title="DalzielK , GoingS , CartwrightPH , MarksR , BeveridgeGW , RowellNR . Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). British Journal of Dermatology1986;115(2):211‐6. [PUBMED: 3091062] ">Dalziel 1986</a>), clofazimine (<a href="./references#CD002954-bbs2-0065" title="MackeyJP , BarnesJ . Clofazimine in the treatment of discoid lupus erythematosus. British Journal of Dermatology1974;91(1):93‐6. [PUBMED: 4851057] ">Mackey 1974</a>), retinoids (<a href="./references#CD002954-bbs2-0079" title="RuzickaT , MeurerM , BieberT . Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Archives of Dermatology1988;124(6):897‐902. [PUBMED: 2967674] ">Ruzicka 1988</a>; <a href="./references#CD002954-bbs2-0081" title="ShornickJK , FormicaN , ParkeAL . Isotretinoin for refractory lupus erythematosus. Journal of the American Academy of Dermatology1991;24(1):49‐52. [PUBMED: 1999529] ">Shornick 1991</a>), methotrexate (<a href="./references#CD002954-bbs2-0054" title="GoldsteinE , CareyW . Discoid lupus erythematosus: successful treatment with oral methotrexate. Archives of Dermatology1994;130(7):938‐9. [PUBMED: 8024288] ">Goldstein 1994</a>), azathioprine (<a href="./references#CD002954-bbs2-0084" title="TsokosGC , CaughmanSW , KlippelJH . Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Archives of Dermatology1985;121(10):1323‐5. [PUBMED: 4037829] ">Tsokos 1985</a>), lenalidomide (<a href="./references#CD002954-bbs2-0071" title="OkonL , RosenbachM , KrathenM , RoseM , PropertK , OkawaJ , et al. Lenalidomide in treatment‐refractory cutaneous lupus erythematosus: Efficacy and safety in a 52‐week trial. Journal of American Academy of Dermatology2014;70(3):583‐4. [PUBMED: 24528907] ">Okon 2014</a>), thalidomide (<a href="./references#CD002954-bbs2-0055" title="HasperMF . Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Archives of Dermatology1983;119(10):812‐5. [PUBMED: 6614949] ">Hasper 1983</a>; <a href="./references#CD002954-bbs2-0060" title="KnopJ , BonsmannG , HappleR , LudolphA , MatzDR , MifsudEJ , et al. Thalidomide in the treatment of 60 cases of chronic discoid lupus erythematosus. British Journal of Dermatology1983;108:461‐6. ">Knop 1983</a>; <a href="./references#CD002954-bbs2-0069" title="NaafsB , FaberWR . Thalidomide therapy. An open trial. International Journal of Dermatology1985;24(2):131‐4. [PUBMED: 2985516] ">Naafs 1985</a>), topical salbutamol (<a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>), sulphasalazine (<a href="./references#CD002954-bbs2-0040" title="ArtuzF , LenkN , DenizN , AlliN . Efficacy of sulphasalazine in discoid lupus erythematosus. International Journal of Dermatology1996;35(10):746‐8. [PUBMED: 8891833] ">Artuz 1996</a>), phenytoin (<a href="./references#CD002954-bbs2-0077" title="Rodriguez‐CastellanosMA , Barba RubioJ , Barba GomezJF , Gonzalez MendozaA . Phenytoin in the treatment of discoid lupus erythematosus. Archives of Dermatology1995;131(5):620‐1. [PUBMED: 7741559] ">Rodriguez‐Castellanos 1995</a>), interferon alpha‐2a (<a href="./references#CD002954-bbs2-0068" title="MartinezJ , deMisaRF , TorreloA , LedoA . A low‐dose intralesional interferon alfa for discoid lupus erythematosus. Journal of the American Academy of Dermatology1992;26(3 Pt 2):494‐6. [PUBMED: 1564159] ">Martinez 1992</a>), topical calcineurin blockers (pimecrolimus and tacrolimus) (<a href="./references#CD002954-bbs2-0088" title="WollinaU , HanselG . The use of topical calcineurin inhibitors in lupus erythematosus: an overview. Journal of the European Academy of Dermatology and Venereology : JEADV2008;22(1):1‐6. [PUBMED: 18005117] ">Wollina 2007</a>; <a href="./references#CD002954-bbs2-0083" title="TzellosTG , KouvelasD . Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence‐based evaluation. European Journal of Clinical Pharmacology2008;64(4):337‐41. [PUBMED: 18157526] ">Tsellos 2008</a>), and biological agents such as abatacept (<a href="./references#CD002954-bbs2-0019" title="MerrillJT , Burgos‐VargasR , WesthovensR , ChalmersA , D'CruzD , WallaceDJ , et al. The efficacy and safety of abatacept in patients with non‐life‐threatening manifestations of systemic lupus erythematosus: results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2010;62(10):3077‐87. [PUBMED: 20533545] ">Merrill 2010a</a>), belimumab (<a href="./references#CD002954-bbs2-0018" title="ManziS , Sánchez‐GuerreroJ , MerrillJT , FurieR , GladmanD , NavarraSV , et al. Effects of belimumab, a B lymphocyte stimulator‐specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases2012;71(11):1833‐8. [PUBMED: 22550315] ">Manzi 2012</a>), efalizumab (<a href="./references#CD002954-bbs2-0085" title="UsmaniN , GoodfieldM . Efalizumab in the treatment of discoid lupus erythematosus. Archives of Dermatology2007;143(7):873‐7. [PUBMED: 17638731] ">Usmani 2007</a>), etanercept, infliximab, rituximab, sifalimumab (<a href="./references#CD002954-bbs2-0021" title="MerrillJT , WallaceDJ , PetriM , KirouKA , YaoY , WhiteWI , et al. Safety profile and clinical activity of sifalimumab, a fully human anti‐interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double‐blind randomised study. Annals of the Rheumatic Diseases2011;70(11):1905‐13. [PUBMED: 21798883] ">Merrill 2011</a>) and sirukumab (<a href="./references#CD002954-bbs2-0023" title="SzepietowskiJC , NilganuwongS , WozniackaA , KuhnA , NybergF , vanVollenhovenRF , et al. Phase I, randomized, double‐blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis and Rheumatism2013;65(10):2661‐71. [PUBMED: 23896980] ">Szepietowski 2013</a>) </p> </section> <section id="CD002954-sec-0033"> <h3 class="title" id="CD002954-sec-0033">How the intervention might work</h3> <p>Steroids have anti‐inflammatory and immunosuppressive effects, acting on genetic material in the cell nucleus, via steroid receptors in the cell (<a href="./references#CD002954-bbs2-0070" title="NorrisDA . Mechanisms of action of topical therapies and the rationale for combination therapy. Journal of the American Academy of Dermatology2005;53(1 Suppl 1):S17‐25. [PUBMED: 15968260] ">Norris 2005</a>). Tacrolimus and pimecrolimus, which are calcineurin inhibitors, inhibit the activity of T lymphocytes (via calcium channels), a key cell in the development of cutaneous lupus (<a href="./references#CD002954-bbs2-0058" title="KhandpurS , SharmaVK , SumanthK . Topical immunomodulators in dermatology. Journal of Postgraduate Medicine2004;50(2):131‐9. [PUBMED: 15235214] ">Khandpur 2004</a>). Salbutamol may exert an anti‐inflammatory effect by activating receptors on the surface of cells, particularly lymphocytes and eosinophils (<a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>). Evidence suggests that chloroquine and hydroxychloroquine which are antimalarials, have an effect on inflammation by reducing antigen presentation and the production of inflammatory cytokines (<a href="./references#CD002954-bbs2-0074" title="RainsfordKD , ParkeAL , Clifford‐RashotteM , KeanWF . Therapy and pharmacological properties of hydroxychloroquine and chloroquine in systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology2015;23(5):231‐69. [PUBMED: 26246395] ">Rainsford 2015</a>). The anti‐inflammatory mechanism of action of retinoids, such as acitretin, are not fully understood. Retinoid receptors allow access to the cell nucleus, and retinoids promote normal cell growth (<a href="./references#CD002954-bbs2-0080" title="SchroederM , ZouboulisCC . All‐trans‐retinoic acid and 13‐cis‐retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes. Hormone Metabolism Research2007;39(2):136‐40. [PUBMED: 17326009] ">Schroeder 2007</a>). </p> </section> <section id="CD002954-sec-0034"> <h3 class="title" id="CD002954-sec-0034">Why it is important to do this review</h3> <p>Permanent scarring is likely if treatment is delayed or inadequate. People with DLE often experience great emotional distress. Social isolation and difficulty obtaining work are frequent problems. The relative efficacies of possible forms of treatment compared to placebo or each other need to be clearly established. Some of these agents (such as the cytotoxics) are potentially toxic (<a href="./references#CD002954-bbs2-0087" title="WeinblattME . Methotrexate in rheumatoid arthritis: a quarter century of development. Transactions of the American Clinical and Climatological Association2013;124:16‐25. [PUBMED: 23874006] ">Weinblatt 2013</a>; <a href="./references#CD002954-bbs2-0052" title="GoldbergR , IrvingP . Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Review of Gastroenterology &amp; Hepatology2015;9(7):891‐900. [PUBMED: 25915575] ">Goldberg 2015</a>). Both thalidomide and the retinoids are highly teratogenic (they may cause birth defects when given to pregnant women), which renders their use in fertile women problematic (<a href="./references#CD002954-bbs2-0072" title="OrtizNE , NijhawanRI , WeinbergJM . Acitretin. Dermatologic Therapy2013;26(5):390‐9. [PUBMED: 24099069] ">Ortiz 2013</a>; <a href="./references#CD002954-bbs2-0089" title="ZhouS , WangF , HsiehTC , WuJM , WuE . Thalidomide ‐ a notorious sedative to a wonder anticancer drug. Current Medicinal Chemistry2013;20(33):4102‐8. [PUBMED: 23931282] ">Zhou 2013</a>). It is this combination of uncertainty of relative effectiveness and some potential to cause considerable harm that has fuelled the need for this systematic review. This is an update of a Cochrane Review first published in 2000 (<a href="./references#CD002954-bbs2-0090" title="JessopS , WhitelawD , JordaanF . Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD002954] ">Jessop 2000</a>); and previously updated in 2009 (<a href="./references#CD002954-bbs2-0091" title="JessopS , WhitelawDA , DelamereFM . Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD002954.pub2] ">Jessop 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002954-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002954-sec-0035"></div> <p>To assess the effects of drugs for discoid lupus erythematosus.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002954-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002954-sec-0036"></div> <section id="CD002954-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002954-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials of drug therapy for discoid lupus erythematosus.</p> </section> <section id="CD002954-sec-0039"> <h4 class="title">Types of participants</h4> <p>Participants at least 18 years of age.</p> <p>A clinical diagnosis of discoid lupus erythematosus was accepted, with or without histological confirmation. Studies that enrolled people with different types of cutaneous lupus were included if the subgroup with DLE could be identified separately. </p> </section> <section id="CD002954-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Any drug treatment aimed at clearing or improving the lesions of DLE. This included:</p> <p> <ul id="CD002954-list-0001"> <li> <p>chloroquine, hydroxychloroquine, and other anti‐malarial quinines;</p> </li> <li> <p>thalidomide and lenalidomide;</p> </li> <li> <p>steroids, topical and systemic;</p> </li> <li> <p>retinoids, including acitretin, etretinate, isotretinoin;</p> </li> <li> <p>azathioprine;</p> </li> <li> <p>methotrexate;</p> </li> <li> <p>dapsone;</p> </li> <li> <p>clofazimine;</p> </li> <li> <p>phenytoin;</p> </li> <li> <p>gold;</p> </li> <li> <p>sulphasalazine;</p> </li> <li> <p>interferon alpha‐2a;</p> </li> <li> <p>biological agents, including abatacept, adalimumab, belimumab, etanercept, efalizumab, infliximab, rituximab, sifalimumab and sirukumab; </p> </li> <li> <p>topical calcineurin antagonists, including tacrolimus, pimecrolimus;</p> </li> <li> <p>topical salbutamol.</p> </li> </ul> </p> <p>Potentially, any of these interventions could have been compared with placebo or with any other intervention. Delivery of the drug could be topical, parenteral or oral. </p> <p>We excluded surgery, laser, photoprotection, phototherapy, and other forms of physical therapy as we did not consider them drug treatments. </p> </section> <section id="CD002954-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD002954-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002954-list-0002"> <li> <p>Percentage of people with complete resolution of skin lesions (i.e. return to normal skin appearance). </p> </li> <li> <p>Percentage of people with clearing of erythema in at least 50% of lesions (post‐inflammatory pigmentation could persist). </p> </li> <li> <p>Improvement in patient satisfaction/quality of life measures.</p> </li> </ul> </p> </section> <section id="CD002954-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002954-list-0003"> <li> <p>Relapse rate when medication stopped or reduced.</p> </li> <li> <p>Prevention of new lesions.</p> </li> <li> <p>Adverse effects of medication, leading to discontinuation or significant morbidity.</p> </li> <li> <p>Implications for health care costs.</p> </li> </ul> </p> </section> </section> </section> <section id="CD002954-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD002954-sec-0045"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised the search strategies for CENTRAL, MEDLINE and Embase in line with current Cochrane Skin practices, and we re‐ran our existing searches for the other databases. Details of the previous search strategies are available in <a href="./references#CD002954-bbs2-0090" title="JessopS , WhitelawD , JordaanF . Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD002954] ">Jessop 2000</a> and <a href="./references#CD002954-bbs2-0091" title="JessopS , WhitelawDA , DelamereFM . Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD002954.pub2] ">Jessop 2009</a>. </p> <p>We searched the following up to 22 September 2016.</p> <p> <ul id="CD002954-list-0004"> <li> <p>Cochrane Skin Specialised Register using the following terms: ((discoid and lupus) or (cutaneous and lupus)) and erythematosus. </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library using the search strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=218899080516180107%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>. </p> </li> <li> <p>MEDLINE Ovid (from 1946) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=218899080516180107%26format=REVMAN#APP-03" target="_blank">Appendix 3</a>. </p> </li> <li> <p>Embase Ovid (from 1974) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=218899080516180107%26format=REVMAN#APP-04" target="_blank">Appendix 4</a>. </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=218899080516180107%26format=REVMAN#APP-05" target="_blank">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD002954-sec-0046"> <h5 class="title">Trials Registries and Portals</h5> <p>We searched the following trials registries and portals to 20 September 2016 using the following search terms. </p> <p>1. Discoid lupus erythematosus.<br/> 2. Skin lupus erythematosus.<br/> 3. Cutaneous lupus erythematosus. </p> <p> <ul id="CD002954-list-0005"> <li> <p>ISRCTN registry (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>). </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD002954-sec-0047"> <h4 class="title">Searching other resources</h4> <section id="CD002954-sec-0048"> <h5 class="title">Handsearching</h5> <p>We hand searched Index Medicus for studies relating to treatment of discoid lupus erythematosus for the years 1956 to 1966. </p> </section> <section id="CD002954-sec-0049"> <h5 class="title">References from published studies</h5> <p>We checked the bibliographies of included studies for further references to relevant trials. </p> </section> <section id="CD002954-sec-0050"> <h5 class="title">Correspondence</h5> <p>We approached seven experts in the field of DLE treatment in an attempt to identify other relevant studies, including unpublished trials and dissertations. We asked three pharmaceutical companies for records of unpublished trials. </p> <p>We approached authors of registered but unpublished trials requesting their results.</p> </section> <section id="CD002954-sec-0051"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target intervention. However, we recorded all adverse events in <a href="./references#CD002954-sec-0123" title="">Characteristics of included studies</a> and and <a href="./references#CD002954-sec-0124" title="">Characteristics of excluded studies</a>.  </p> </section> </section> </section> <section id="CD002954-sec-0052"> <h3 class="title" id="CD002954-sec-0052">Data collection and analysis</h3> <p>SJ and DW, with PJ's assistance, extracted the data independently and resolved differences by discussion. </p> <p>MG examined and described the statistical information in individual trials and edited or wrote the sections on measures of treatment effect, data synthesis and unit of analysis issues and created the 'Summary of findings' tables. </p> <section id="CD002954-sec-0053"> <h4 class="title">Selection of studies</h4> <p>We (SJ, DW, PJ) screened the titles and abstracts and independently selected them for inclusion or exclusion. We resolved disagreements by discussion. </p> </section> <section id="CD002954-sec-0054"> <h4 class="title">Data extraction and management</h4> <p>We (SJ, DW) extracted trial characteristics and outcomes, independently, and recorded the data on a data extraction sheet. We resolved disagreements by discussion. </p> </section> <section id="CD002954-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We (SJ, DW, MG) assessed the risk of bias and the methodological quality of included studies independently, using the following components of internal and external validity for each included study, as outlined in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD002954-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>a) The method of generation of the randomisation sequence.<br/> b) The method of allocation concealment.<br/> c) Who was blinded and not blinded.<br/> d) The number of participants lost to follow‐up and the reasons provided for these losses.<br/> e) Whether outcomes were analysed according to the intention‐to‐treat principle.<br/> f) Comparability of the two treatment groups in each arm. </p> <p>MG checked assessments in case of discrepancy.</p> </section> <section id="CD002954-sec-0056"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (primary outcomes 1 and 2 and adverse events), results are presented as risk ratios (RR) with 95% confidence intervals (CI). Where the first treatment in the comparison is beneficial (RR &gt; 1 for efficacy outcomes), we presented the number needed to treat for an additional beneficial outcome (NNTB) for any significant outcomes (P &lt; 0.05). We planned to present the number needed to treat for an additional harmful outcome (NNTH) where the first treatment in the comparison is harmful (RR &gt; 1 for safety outcomes) for any significant adverse outcomes (P &lt; 0.05). </p> <p>Where results were estimated for individual studies with low numbers of outcomes (&lt; 10 in total) or where the total sample size were less than 30 participants, we planned to report the proportion of outcomes in each treatment group, together with a P value from a Fisher’s Exact test (obtained using the "tabi" calculator in Stata version 14). </p> <p>For continuous outcomes (primary outcome 3), we planned to present results in the form of mean differences (with 95% CIs). Where there were treatment comparisons where studies used different scales for the same outcome, we planned to convert results to standard mean differences (SMD) to allow pooling of results. </p> </section> <section id="CD002954-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <section id="CD002954-sec-0058"> <h5 class="title">Cross‐over trials</h5> <p>We followed the guidance provided in Section 16.4.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002954-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Where no evidence of a carry‐over effect was present, analyses of paired differences were presented if these data could be obtained from the trial report. Otherwise, only data from the first treatment period were used. </p> </section> <section id="CD002954-sec-0059"> <h5 class="title">Within‐patient studies</h5> <p>Internally controlled trials were analysed using techniques for paired designs (e.g. paired t‐test, McNemar's test). Where appropriate, these were included in additional data tables and not pooled with parallel group trials. </p> </section> </section> <section id="CD002954-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>The use of 'intention‐to‐treat' analysis was reported in the 'Risk of bias' tables of the 'Characteristics of included studies' tables. SJ wrote to five authors and received a response from three authors; some of the investigators in trial registries did not supply contact details. </p> </section> <section id="CD002954-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to test statistical heterogeneity using the I² statistic (0% to 40%: may not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: represents considerable heterogeneity) (<a href="./references#CD002954-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), However, assessment of heterogeneity was not performed as no findings were based on pooled results from two or more trials. If in future updates meta‐analyses are performed, the heterogeneity will be quantified using the I² statistic. In cases of substantial heterogeneity (I² &gt; 80%), studies will not be pooled and instead reasons for heterogeneity will be explored. </p> </section> <section id="CD002954-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>Assessment for reporting bias was not possible in the present review as this contained no pooled results from meta‐analyses. </p> <p>If in future updates of this review there are 10 studies or more of any single intervention, funnel plots will be used to evaluate asymmetry, using Egger's method (<a href="./references#CD002954-bbs2-0048" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐634. [PUBMED: 9310563] ">Egger 1997</a>), as described in section 10.4.3.1 of the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002954-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). A degree of reporting bias was identified in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, with details of erythema not reported, although this was described as part of the outcome score. Difference in erythema was not statistically significant. </p> </section> <section id="CD002954-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We planned to draw up a synthesis of included trials; however, this was not possible with the data in the studies we found, due to heterogeneity of study methods and interventions. No two trials investigated the same interventions. If in future updates of the review it is possible to pool results then we will use random effects meta‐analysis for both dichotomous and continuous outcomes to account for the anticipated heterogeneity between studies. </p> </section> <section id="CD002954-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the protocol, we had planned to perform subgroup analysis on the following measures: disseminated DLE versus localised DLE; DLE with systemic lupus versus DLE without systemic lupus; histologically proven versus clinically diagnosed DLE; and effect of ethnic group on outcome. However subgroup analysis was not possible in this update. </p> <section id="CD002954-sec-0065"> <h5 class="title">Other</h5> <p>We planned where possible to calculate cost effectiveness ratios using quality‐of‐life measures; however, the studies identified did not provide these data. </p> </section> </section> <section id="CD002954-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were not carried out as no findings from this review were based on pooled results from two or more studies. If in future updates of this review pooled results are presented, sensitivity analyses will be carried out restricting results to studies assessed as being at low risk of bias for all of the following three domains: allocation concealment; blinding of participants and outcomes assessors; and incomplete outcome data (<a href="./references#CD002954-bbs2-0056" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD002954-sec-0067"> <h5 class="title">'Summary of findings' table</h5> <p>'Summary of findings' tables as detailed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> were produced from within Review Manager 5 (RevMan 5) software (<a href="https://archie.cochrane.org/sections/documents/view?document=z1407181809005368162413537309618%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>). In these, we have summarised the primary outcomes for the most important comparisons (<a href="./full#CD002954-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD002954-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002954-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002954-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD002954-tbl-0005">summary of findings Table 5</a>). Confidence intervals for the corresponding risk were calculated using <a href="https://archie.cochrane.org/sections/documents/view?document=z1407181809005368162413537309618%26format=REVMAN#REF-GRADEpro-2008" target="_blank">GRADEpro 2008</a> software. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002954-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002954-sec-0068"></div> <section id="CD002954-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD002954-sec-0070"> <h4 class="title">Results of the search</h4> <p>We retrieved 71 records from the searches for the 2009 review (<a href="./references#CD002954-bbs2-0091" title="JessopS , WhitelawDA , DelamereFM . Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD002954.pub2] ">Jessop 2009</a>), of which two met the criteria for inclusion (<a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> and <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>). Literature searches in 2014, 2015, and 2016 yielded a further 155 studies. We identified 12 studies from our searches of trials registers. In total we screened 238 records. We excluded 202 records on the basis of titles and abstracts. Of the remaining 36 records, one article was not available in full text and has been added to studies awaiting classification (<a href="./references#CD002954-bbs2-0037" title="PothinamthongP , JanjumratsangP . A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. Journal of the Medical Association of Thailand= Chotmaihet Thangphaet2012;95(7):933‐40. [PUBMED: 22919989] ">Pothinamthong 2012</a>) along with eight trials registry records (see <a href="./references#CD002954-sec-0125" title="">Characteristics of studies awaiting classification</a>). One study is ongoing (see <a href="./references#CD002954-sec-0126" title="">Characteristics of ongoing studies</a>). The remaining 26 articles were assessed in full text for eligibility. </p> <p>Of the 26 full texts, we excluded 23 studies (14 did not describe outcomes in the DLE group specifically and others were excluded because they referred to photoprotection trials and not drug trials or were not RCTs) (see <a href="./references#CD002954-sec-0124" title="">Characteristics of excluded studies</a>). We included three new studies in this update (<a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>, <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, and <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>), giving a total of five included studies altogether (see <a href="./references#CD002954-sec-0123" title="">Characteristics of included studies</a>). We noted that diagnosis of DLE was generally based on clinical judgement in the early studies, but investigators required histological (skin biopsy) confirmation in the three new studies. </p> <p>Of the nine drug trials of DLE listed in <a href="./references#CD002954-sec-0125" title="">Characteristics of studies awaiting classification</a>, the interventions included etanercept, other biologics, R‐salbutamol, pimecrolimus, and an oral retinoid, alitretinoin. Half of the studies were described as complete but results have not yet been published. We attempted to contact two of the investigators, without success. One investigator reported that their study did not include analysis of the subset with DLE. </p> <p>For a summary of our screening process see <a href="#CD002954-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD002954-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD002954-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD002954-sec-0071"> <h4 class="title">Included studies</h4> <p>We included five studies, three of which were new. The full details are in the <a href="./references#CD002954-sec-0123" title="">Characteristics of included studies</a> table. There were a total of 197 participants (see sample sizes). </p> <section id="CD002954-sec-0072"> <h5 class="title">Design</h5> <p>The first study, involving 78 people, was a double‐blind RCT comparing two steroid creams of different potencies (<a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>). The creams were prepared in the same cream base and identical tubes, and were compared in a 12‐week cross‐over trial. A single active lesion on each person was chosen for monitoring. One of the creams was applied for 6 weeks, then the other for a further 6 weeks. Only the outcome prior to cross‐over was included in the analysis for this review. </p> <p>The second trial was a double‐blind RCT, over 8 weeks (<a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>). </p> <p>The third trial, was a double‐blind RCT, over 8 weeks (<a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>). </p> <p>In <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, an active agent was compared with placebo, in a double‐blind RCT. The creams were identical. </p> <p>A 2011 trial was a double‐blind placebo‐controlled RCT, over 12 weeks (<a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>). The vehicle was used as the placebo, to ensure blinding. </p> </section> <section id="CD002954-sec-0073"> <h5 class="title">Sample sizes</h5> <p>There were a total of 197 participants in the five trials: 78 in <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980;</a> 58 in <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992;</a> 10 in <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009;</a> 37 in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>; and 14 in the study by <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>. </p> </section> <section id="CD002954-sec-0074"> <h5 class="title">Setting</h5> <p>The setting of <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> was not stated. <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>, <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>, <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> and <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> were set in specialised lupus clinics, as most people with DLE were attending such clinics. </p> </section> <section id="CD002954-sec-0075"> <h5 class="title">Participants</h5> <p><a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> randomised for inclusion 32 men and 61 women, aged 17 to 82 years, from the following ethnic groups: 23 black American, and 25 white American in one group; and 23 black American, and 22 white American in the other. The duration of their disease was very variable (1 to 240 months). There were no significant differences between people in the two arms, in terms of demographics or duration of disease. All participants had chronic DLE. However final number of participants was 78, (others excluded at onset) and ethnic and gender breakdown of participating group was not supplied. </p> <p>In <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>, there were 22 men and 36 women, with a mean age of 43.3 years. The ethnic group was not mentioned. All participants had cutaneous lupus, 39 discoid and 19 subacute LE. People with subacute LE were more highly represented in the hydroxychloroquine arm. </p> <p>In <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> , participants were Iranian, aged 20 to 53, and 7 of the 10 were women. Participants in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> included 28 women and 9 men, aged 34 to 72. There was no ethnicity provided. In the <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> trial, there were six women and eight men with DLE, with a mean age of 49.8 ± 5.9. Ethnicity was not supplied. </p> </section> <section id="CD002954-sec-0076"> <h5 class="title">Interventions</h5> <p><a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> compared two topical steroids, fluocinonide 0.05% (potent steroid) and hydrocortisone 1% (mild steroid) in the same cream base. </p> <p><a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> compared two oral agents, acitretin (a synthetic retinoid) and hydroxychloroquine (an anti‐malarial). </p> <p><a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> compared pimecrolimus 1% cream with betamethasone 17‐valerate 0.1% cream. </p> <p><a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> compared salbutamol 0.5% cream with placebo (same vehicle, so indistinguishable). </p> <p><a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> compared tacrolimus 0.1% cream with placebo (vehicle). </p> </section> <section id="CD002954-sec-0077"> <h5 class="title">Outcomes</h5> <p>In <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>, the outcome was based on the authors' own 5‐point scale, using a single test site. The investigators used a scale, providing a score of 1 if the lesion became worse, 2 if there was no improvement, 3 if there was a little improvement, 4 if improvement was marked, and 5 if the lesion cleared or showed excellent improvement. There was no assessment by the participants. </p> <p>Assessment of severity in <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> was based on an ordinal scale using erythema (redness), infiltration (thickness), and scaling with complete clearing graded as 0, improvement as 1, and no change or deterioration as 2. Extent of skin disease and the occurrence of adverse reactions were also documented. </p> <p><a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> used digital photographs, which were examined by three blinded dermatologists, using a severity score. </p> <p><a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> reported outcomes using the CLASI score, the clinician's global assessment and the participant's global assessment. </p> <p><a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> used digital photography and a clinical assessment, using a clinical score. They reported adverse events. </p> <p>Quality‐of‐life measures or participant global evaluation were not recorded in any of the studies. </p> </section> </section> <section id="CD002954-sec-0078"> <h4 class="title">Excluded studies</h4> <p>Details of the 23 excluded studies can be found in the <a href="./references#CD002954-sec-0124" title="">Characteristics of excluded studies</a> table. In 14 studies, participants had systemic or cutaneous lupus, or both, but the group with DLE were not described specifically, so the influence of treatment in DLE could not be established. Seven trials were not randomised. Authors of two excluded RCTs reported results with topical tacrolimus versus topical clobetasol propionate, and clofazimine versus chloroquine diphosphate (<a href="./references#CD002954-bbs2-0007" title="BezerraEL , VilarMJ , deTrindade NetoPB , SatoEI . Double‐blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis and Rheumatism2005;52(10):3073‐8. [PUBMED: 16200586] ">Bezerra 2005</a>; <a href="./references#CD002954-bbs2-0025" title="TzungTY , LiuYS , ChangHW . Tacrolimus vs clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double‐blind, bilateral comparison study. British Journal of Dermatology2007;156(1):163‐201. ">Tzung 2007</a>). However, in both studies participants had various forms of cutaneous lupus and results for individual subsets were not reported separately, thus it was not possible to establish the relative benefits of individual treatments in DLE. <a href="./references#CD002954-bbs2-0006" title="AvgerinouG , PapafragkakiDK , NasiopoulouA , ArapakiA , KatsambasA , StavropoulosPG . Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. Journal of the European Academy of Dermatology and Venereology : JEADV2012;26(6):762‐7. [PUBMED: 21707772] ">Avgerinou 2012</a> was not an RCT and the DLE subset was not reported. <a href="./references#CD002954-bbs2-0011" title="GammonB , HansenC , CostnerMI . Efficacy of mycophenolate mofetil in antimalarial‐resistant cutaneous lupus erythematosus. Journal of the American Academy of Dermatology2011;65(4):717‐21. [PUBMED: 21641078] ">Gammon 2011</a> did not report results for the DLE subset. <a href="./references#CD002954-bbs2-0018" title="ManziS , Sánchez‐GuerreroJ , MerrillJT , FurieR , GladmanD , NavarraSV , et al. Effects of belimumab, a B lymphocyte stimulator‐specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases2012;71(11):1833‐8. [PUBMED: 22550315] ">Manzi 2012</a>, <a href="./references#CD002954-bbs2-0019" title="MerrillJT , Burgos‐VargasR , WesthovensR , ChalmersA , D'CruzD , WallaceDJ , et al. The efficacy and safety of abatacept in patients with non‐life‐threatening manifestations of systemic lupus erythematosus: results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2010;62(10):3077‐87. [PUBMED: 20533545] ">Merrill 2010a</a>, <a href="./references#CD002954-bbs2-0020" title="MerrillJT , NeuweltCM , WallaceDJ , ShanahanJC , LatinisKM , OatesJC , et al. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: the randomized, double‐blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis and Rheumatism2010;62(1):222‐33. [PUBMED: 20039413] ">Merrill 2010b</a>, <a href="./references#CD002954-bbs2-0021" title="MerrillJT , WallaceDJ , PetriM , KirouKA , YaoY , WhiteWI , et al. Safety profile and clinical activity of sifalimumab, a fully human anti‐interferon alpha monoclonal antibody, in systemic lupus erythematosus: A phase I, multicentre, double‐blind randomised study. Annals of the Rheumatic Diseases2011;70(11):1905‐13. [PUBMED: 21798883] ">Merrill 2011</a> and <a href="./references#CD002954-bbs2-0023" title="SzepietowskiJC , NilganuwongS , WozniackaA , KuhnA , NybergF , vanVollenhovenRF , et al. Phase I, randomized, double‐blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis and Rheumatism2013;65(10):2661‐71. [PUBMED: 23896980] ">Szepietowski 2013</a> described people with SLE and did not provide data for the DLE subset. The study of mucosal DLE, comparing tacrolimus ointment and triamcinolone cream by <a href="./references#CD002954-bbs2-0026" title="WangX , ZhangL , LuoJ , WuZ , MeiY , WangY , et al. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized controlled clinical trial. Journal of Clinical Pharmacology2015;55(11):1221‐8. [PUBMED: 25951426] ">Wang 2015</a> had major methodology flaws: participants were not blinded and the basis for diagnosis of DLE was not clear (<a href="./references#CD002954-bbs2-0026" title="WangX , ZhangL , LuoJ , WuZ , MeiY , WangY , et al. Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized controlled clinical trial. Journal of Clinical Pharmacology2015;55(11):1221‐8. [PUBMED: 25951426] ">Wang 2015</a>). </p> <p>We found 12 registered trials in the trial registries. We attempted to contact investigators where the trial was described as completed and had not been published, but very few trial records provided relevant contact details. We received two replies, confirming that people with DLE had not been recorded separately in their trials. </p> </section> </section> <section id="CD002954-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, risk of bias was considered low or unclear for most parameters for the included studies. </p> <p>See <a href="#CD002954-fig-0002">Figure 2</a> for the risk of bias summary of the judgements for each included study. </p> <div class="figure" id="CD002954-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002954-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002954-sec-0080"> <h4 class="title">Allocation</h4> <p>The topical steroid study <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> was randomised and statistical tests for equality confirmed that randomisation was successful; however, no mention was made of allocation concealment. In <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>, comparing hydroxychloroquine and acitretin, participants were randomised but methods taken to conceal the allocation were not stated. </p> <p>In <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>, randomisation was applied by the use of odd and even numbers, (quasi‐randomisation), hence was considered high risk of selection bias from an inadequate random sequence generation. However, the method used would not introduce selection bias from allocation concealment as numbers were assigned on the basis of order of referral, so decisions made (re: participation) could not have been made with knowledge of the treatment to be received. </p> <p>In <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, randomisation was generated from a random number list. However, details as to whether the randomisation list was available to recruiting clinicians was not stated (unclear allocation concealment). </p> <p>In <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>, random numbers were computer generated and allocation was conducted by a pharmacist who was independent of the study investigators (adequate concealment of allocation). </p> </section> <section id="CD002954-sec-0081"> <h4 class="title">Blinding</h4> <p>IParticipant blinding was clearly stated in <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>; however, blinding of outcome assessors was not described (although the trial was described as double blind). <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> was described as double‐blind, but no details were provided. </p> <p>Blinding was described in <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>, with identical jars of test agents. In <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, blinding was described for both assessors and participants. The <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> study similarly used identical containers and both participants and assessors were blinded. </p> </section> <section id="CD002954-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>In the <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> study, data from 78 people were available for analysis at the end of the first phase (six weeks). Fifteen people dropped out during the first phase, 13 because of non‐compliance, and two because of the use of a proscribed drug. Hence, the study was judged at high risk of attrition bias. </p> <p>The remaining studies were at low risk of attrition bias. In <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>, 51 of 58 participants completed the trial (83%). Among those given acitretin, four people dropped‐out because of side‐effects (not detailed), another because of treatment failure, and a sixth due to non‐compliance. In the hydroxychloroquine group three people withdrew from the study prematurely because of complete clearing of skin lesions and one because of failure of treatment. Intention‐to‐treat analysis was used. </p> <p>There were no withdrawals from the <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> trial. </p> <p>In the <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> study, the numbers contributing to the analyses were not stated but it was clearly stated that an intention‐to‐treat analysis was carried out. </p> <p>In the <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> trial, two of the 14 participants with DLE did not complete the trial. Intention to treat analysis was used in a secondary analysis. </p> <p>Overall, ITT analysis was described in three studies: <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>, <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, and <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>. It was not reported in the other two studies and this was a clear potential risk of bias in the <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> trial, as 15 participants were excluded from final analysis. </p> </section> <section id="CD002954-sec-0083"> <h4 class="title">Selective reporting</h4> <p>One study was considered to be at high risk of selective reporting because they authors did not provide details on the impact on erythema (<a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>). In two studies it was unclear if there was selective reporting (<a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>, <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>), while the remaining two studies were judged as low risk (<a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009,</a><a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>), as all expected outcomes were reported. </p> </section> <section id="CD002954-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>Overall, it was unclear whether studies were at risk of other potential sources of bias, except for <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> where high clinical heterogeneity was identified; hence, was judged as high risk of other bias. Studies were also assessed separately for 'Comparability of the two arms', see below. </p> <section id="CD002954-sec-0085"> <h5 class="title">Comparability of the two arms</h5> <p>The risk of bias was rated as low in four studies. In the <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> trial, the groups were comparable at baseline. The participants in the two arms in the <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> study had similar active lesions at baseline (activity scores 1.32 ± 0.48 vs 1.11 ± 0.47). The mean disease severity score was similar between the two groups at baseline in the <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> study. <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> also had comparable arms at baseline. </p> <p><a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> included 19 people with subacute cutaneous lupus erythematosus. As people with this form of cutaneous lupus were more strongly represented in the chloroquine group, this might have influenced the outcome of treatment, as people with subacute lupus may have a better response rate. The response rates for discoid lupus and subacute lupus were not described separately. Hence, this study was judged to be at high risk of bias. </p> <p>We are of the opinion that none of the five studies included in this review are affected by other potential threats to validity, including: </p> <p> <ul id="CD002954-list-0006"> <li> <p>interim results analysis;</p> </li> <li> <p>deviation from study protocol not reflecting clinical practice;</p> </li> <li> <p>prerandomisation of the intervention which could affect the result;</p> </li> <li> <p>contamination of drugs (pooling of drugs by participants);</p> </li> <li> <p>overly wide inclusion criteria for participants;</p> </li> <li> <p>use of insensitive instruments to measure outcomes;</p> </li> <li> <p>selective reporting of subgroups;</p> </li> <li> <p>inappropriate influence of funders.</p> </li> </ul> </p> </section> </section> </section> <section id="CD002954-sec-0086"> <h3 class="title" id="CD002954-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD002954-tbl-0001"><b>Summary of findings for the main comparison</b> Fluocinonide 0.05% compared with hydrocortisone 1%</a>; <a href="./full#CD002954-tbl-0002"><b>Summary of findings 2</b> Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily</a>; <a href="./full#CD002954-tbl-0003"><b>Summary of findings 3</b> Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1%</a>; <a href="./full#CD002954-tbl-0004"><b>Summary of findings 4</b> R‐salbutamol 0.5% topical cream compared with placebo</a>; <a href="./full#CD002954-tbl-0005"><b>Summary of findings 5</b> Tacrolimus 0.1% cream compared with placebo</a> </p> <section id="CD002954-sec-0087"> <h4 class="title">Primary outcomes</h4> <p> <ul id="CD002954-list-0007"> <li> <p>Percentage of people with complete resolution of skin lesions (i.e. return to normal skin appearance). </p> </li> <li> <p>Percentage of people with clearing of erythema in at least 50% of lesions (post‐inflammatory pigmentation could persist). </p> </li> <li> <p>Improvement in patient satisfaction/quality‐of‐life measures.</p> </li> </ul> </p> <section id="CD002954-sec-0088"> <h5 class="title">Percentage of people with complete resolution of skin lesions (i.e. return to normal skin appearance) </h5> <p>Note that we accepted the following terms to describe complete resolution: complete clearing, clearing, marked improvement and excellent improvement. </p> <p>In the <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> study fluocinonide 0.05% cream appeared to be superior to hydrocortisone 1% cream (low‐potency steroid) in the treatment of discoid lupus erythematosus (<a href="./full#CD002954-tbl-0001">summary of findings Table for the main comparison</a>). At the 6‐week cross‐over point, clearing or excellent improvement was found in 10 out of 37 people (27%) using fluocinonide and in four out of 41 people (10%) using hydrocortisone (RR 2.77, 95% CI 0.95 to 8.08), 1 study, n = 78, low‐quality evidence) (<a href="./references#CD002954-fig-0003" title="">Analysis 1.1</a>). This shows an absolute benefit of potent steroid of 17% (95% CI 0 to 34%). The quality of evidence for this outcome was judged to be low. </p> <p>In the <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> study, the overall outcome appeared similar in the hydroxychloroquine 400 mg and acitretin 50 mg groups (<a href="./full#CD002954-tbl-0002">summary of findings Table 2</a>). There was marked improvement or complete clearing in 13 out of 28 (46%) participants given acitretin and in 15 out of 30 (50%) of those on hydroxychloroquine; i.e. there was no significant difference between the two groups (RR 0.93, 95% CI 0.54 to 1.59) (<a href="./references#CD002954-fig-0004" title="">Analysis 2.1</a>).The quality of evidence for this outcome was judged to be low. </p> <p>In the <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> study, those treated with pimecrolimus 1% had an 86% reduction in severity score compared to 73% in the betamethasone 17‐valerate 0.1% cream group (P = 0.1). The number of participants with complete resolution could not be obtained from the paper (<a href="./full#CD002954-tbl-0003">summary of findings Table 3</a>). </p> <p>In the study by <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, the number of participants with complete resolution could not be obtained from the paper (<a href="./full#CD002954-tbl-0004">summary of findings Table 4</a>). </p> <p>In the <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> study looking at tacrolimus 0.1% cream versus placebo (vehicle), no participants with DLE were reported as having experienced complete clearing (<a href="./full#CD002954-tbl-0005">summary of findings Table 5</a>). The quality of evidence for this outcome was judged to be low. </p> </section> <section id="CD002954-sec-0089"> <h5 class="title">Percentage of people with clearing of erythema in at least 50% of lesions (postinflammatory pigmentation could persist) </h5> <p>In none of the studies was there a measurement of the percentage of participants with clearing of erythema in at least 50% of lesions. </p> <p><a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> used a score that included erythema to measure outcome, but did not report the erythema separately. In the <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> study the effect on erythema was assessed using an ordinal scale where complete clearing was graded as 0 and improvement as 1, so we take this to mean there was clearing of erythema in at least 50% of lesions. Erythema showed more marked improvement in the hydroxychloroquine 400 mg group and more people in this group showed complete clearing compared to those taking acitretin 50 mg, although the result was not statistically significant. There was complete clearing or marked improvement of erythema in 10/24 (42%) of participants in the acitretin group compared to 17/25 (68%) in the hydroxychloroquine group (RR 0.61, 95% CI 0.36 to 1.06) (<a href="./references#CD002954-fig-0005" title="">Analysis 2.2</a>.) The quality of evidence for this outcome was judged to be low. </p> <p>While <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> recorded erythema in treated sites as part of the clinical score, results for erythema were not reported separately. </p> <p>In the <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> study, there was no significant improvement in erythema, but the actual data were not provided. </p> <p>In the <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> study, erythema was included in the clinical score, but actual data were not provided. </p> </section> <section id="CD002954-sec-0090"> <h5 class="title">Improvement in participant satisfaction/quality of life measures</h5> <p>There was no record of any measurements of participant satisfaction or quality of life in any of the included studies. <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> and <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> recorded itch and pain as reported by participants, but no global score or assessment of quality of life. </p> </section> </section> <section id="CD002954-sec-0091"> <h4 class="title">Secondary outcomes</h4> <p> <ul id="CD002954-list-0008"> <li> <p>Relapse rate when medication stopped or reduced.</p> </li> <li> <p>Prevention of new lesions.</p> </li> <li> <p>Adverse effects of medication, leading to discontinuation or significant morbidity.</p> </li> <li> <p>Implications for health care costs.</p> </li> </ul> </p> <section id="CD002954-sec-0092"> <h5 class="title">Relapse rate when medication stopped or reduced</h5> <p>There was no explicit record of relapse rates when medication was stopped in three of the studies. <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> reported that there was no relapse at eight weeks, after stopping the trial medication at four weeks. The trial of <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> reported improvement in skin lesions at four and eight weeks but the benefit was not maintained at 12 weeks. Thus the skin condition had relapsed while the participants were still using the trial cream, tacrolimus 0.1%. </p> </section> <section id="CD002954-sec-0093"> <h5 class="title">Prevention of new lesions</h5> <p>In none of the studies was this outcome directly measured.</p> </section> <section id="CD002954-sec-0094"> <h5 class="title">Adverse effects of medication, leading to discontinuation or significant morbidity</h5> <p>In the <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> study, adverse effects were minor and were seen in both groups (moderate‐quality evidence). Skin irritation occurred in three people using hydrocortisone cream 1% and burning occurred in two people using fluocinonide cream 0.05%. One person in the hydrocortisone group developed acne. The trial was too short to assess other side‐effects, such as skin atrophy (thinning) or capillary damage. </p> <p>In the <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> study, compared with those taking hydroxychloroquine 400 mg adverse effects were more frequent in the acitretin group 50 mg and were more severe, with four participants having to discontinue treatment because of adverse effects (moderate‐quality evidence). The main clinical adverse effects were dry lips/cheilitis (93% of the acitretin and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin and 17% of the hydroxychloroquine group, but no specific information was provided). Laboratory studies revealed changes in triglycerides in both groups, the levels rising from a mean of 1.66 to 2.10 mmol/l in the acitretin group (P = 0.01) and falling from 1.94 to 1.50 mmol/l in the hydroxychloroquine group (P = 0.02). The difference between the two groups was highly significant (P = 0.006). </p> <p>In the <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> study, adverse events were not reported. </p> <p>In the <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> trial there were 39 reported adverse events, 15 in the placebo group and 24 in the salbutamol 0.5% topical cream group (moderate‐quality evidence). None of the adverse events were considered serious and the adverse events did not appear to be related to the trial medication. </p> <p><a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> reported that five people experienced itching or burning at the site of tacrolimus 0.1% cream application, sometimes lasting up to six weeks, and one participant developed herpes simplex infection of the lip during treatment (moderate‐quality evidence). There were no serious adverse events. No adverse events were experienced by the participants using the placebo cream. </p> </section> <section id="CD002954-sec-0095"> <h5 class="title">Implications for healthcare costs</h5> <p>There was no measurement of this outcome in any of the studies.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002954-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002954-sec-0096"></div> <section id="CD002954-sec-0097"> <h3 class="title" id="CD002954-sec-0097">Summary of main results</h3> <p>Five trials are reported in this version of the review, with a total of 197 participants. Three of the studies are new to this update (<a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>; <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>; <a href="./references#CD002954-bbs2-0016" title="KuhnA , LandmannA , PatsinakidisN , RulandV , NozinicS , Perusquia OrtizAM , et al. Fumaric acid ester treatment in cutaneous lupus erythematosus (SLE): a prospective, open‐label, phase II pilot study. Lupus2016;25(12):1357‐64. [PUBMED: 27147621] ">Kuhn 2016</a>). Two of the trials included small numbers of participants (10 in <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> and 14 in <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>). </p> <p>Interventions in the five trials were topical steroids, hydroxychloroquine, acitretin, topical salbutamol, topical tacrolimus, and topical pimecrolimus. </p> <p>The study of topical steroids provides some evidence that a potent steroid cream, fluocinonide 0.05%, may be superior to low‐potency hydrocortisone 1% in the complete resolution of discoid lupus erythematosus skin lesions (<a href="./full#CD002954-tbl-0001">summary of findings Table for the main comparison</a>) (<a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>). The ideal duration of treatment or likelihood of recurrences following treatment has not been established. Our second primary outcome (percentage of people with clearing of erythema in at least 50% of lesions) was not measured. </p> <p>In the comparative trial of hydroxychloroquine 400 mg and acitretin 50 mg (<a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>), no difference in efficacy was demonstrated between the two drugs in terms of the primary outcome, with complete resolution of skin lesions reported in 46% of people taking acitretin and in 50% of those on hydroxychloroquine. Regarding the second primary outcome, 42% of participants taking acitretin showed improvement in erythema in at least 50% of lesions compared with 68% of the hydroxychloroquine group (<a href="./full#CD002954-tbl-0002">summary of findings Table 2</a>). </p> <p>The two studies of calcineurin inhibitors (pimecrolimus 1% and tacrolimus 0.1%) (<a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>; <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>), and the study of R‐salbutamol 0.5% topical cream (<a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>), unfortunately included only 61 participants in all and did not report the primary outcomes of the review (<a href="./full#CD002954-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002954-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD002954-tbl-0005">summary of findings Table 5</a>). </p> <p>There is some evidence that the trial drugs were free of serious side‐effects, but the short duration of most of the trials does not allow any conclusion about long‐term adverse effects of topical steroids. Adverse events were reported in the 12‐week tacrolimus 0.1% study, which was compared to placebo (<a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>), but none were serious. <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> (fluocinonide cream 0.05% vs hydrocortisone cream 1%) was short (six weeks in each arm), and thus side‐effects of long‐term topical steroid use could not be assessed. <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> (acitretin 50 mg vs hydroxychloroquine 400 mg) was the only study that reported discontinuation of participants due to adverse events (four people receiving acitretin discontinued treatment due to dry lips and gastrointestinal symptoms). <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> compared topical salbutamol 0.5% cream with placebo (vehicle), and both groups reported minor adverse events but no serious adverse events. <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> did not present data on adverse events. </p> <p>We are uncertain about the effect of the interventions on patient satisfaction/quality of life, as this primary outcome was not measured by any of our included studies. The secondary outcomes of preventing new lesions and implications for healthcare costs were not assessed in any study either. Relapse rate when medication was stopped or reduced was reported in <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> and <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>. There was no relapse reported in <a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a> at eight weeks, after stopping the trial medication at four weeks; whilst in <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>, participants relapsed by 12 weeks. </p> </section> <section id="CD002954-sec-0098"> <h3 class="title" id="CD002954-sec-0098">Overall completeness and applicability of evidence</h3> <p>The studies in this review have not addressed all the objectives of the review and do not identify the most effective treatment for DLE in all types of participants. </p> <p>The studies identified in this review did not address (or addressed inadequately) the relative benefits of many currently used interventions, against each other or against placebo, including hydroxychloroquine (or chloroquine), retinoids, topical steroids, calcineurin inhibitors, methotrexate, azathioprine, lenalidomide or biological agents. Outcome measures failed to address quality of life measures or, in most cases, relapse rate after medication was stopped. Most studies did not report on complete resolution of skin lesions or clearing of erythema either. Although different populations participated in the trials, there were no trials from Asia, Africa, Australia or South America. </p> </section> <section id="CD002954-sec-0099"> <h3 class="title" id="CD002954-sec-0099">Quality of the evidence</h3> <p>Five trials, involving 197 participants were included. Some primary outcome measures in this review (per cent with complete resolution, percentage with at least 50% improvement in erythema) were inadequately addressed in the majority of included trials. Furthermore, quality of life was not assessed in any of the five included studies. </p> <p>Where quantitative results were provided for primary outcomes, the overall quality of the evidence was judged to be low owing to the small size of most of the studies and high risk of bias on important domains such as incomplete outcome data and non‐comparability of treatment arms at baseline. </p> <p>All trials were judged to be at low risk of bias for blinding as they were all double‐blind and interventions were identical in appearance (although for two studies, <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> and <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>, the methods used to ensure blinding were not fully described). In four studies the method used to generate the allocation sequence was adequate; however, one study was a quasi‐randomised trial where patients were numbered based on time of referral and odd numbered participants were allocated to one treatment and even numbered patients to the other. However, as this study did not include any of our pre‐specified primary or secondary outcome measures (instead a total mean severity score was calculated before and after treatment for each participant), no data for this study were presented in our 'Summary of findings' tables. The method used to conceal allocation was also unclear in three of the studies (<a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>, <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a>; <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>); however, this was judged to be adequate for the other two studies (<a href="./references#CD002954-bbs2-0001" title="BarikbinB , GivradS , YousefiM , EskandariF . Pimecrolimus 1% cream versus betamethasone 17‐valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double‐blind, randomized pilot study. Clinical and Experimental Dermatology2009;34(7):776‐80. [PUBMED: 19456797] ">Barikbin 2009</a>; <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>), For four studies, either the numbers analysed were the same as the number recruited or the number of dropouts was very small, so these were judged to be at low risk of bias for incomplete outcome data. However in the <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> study, 15 of the 78 participants did not contribute data towards the primary outcome of clearing or excellent improvement for reasons which may relate to outcome (<a href="./full#CD002954-tbl-0001">summary of findings Table for the main comparison</a>). Therefore, the quality of evidence on whether there is a difference between fluocinonide and hydrocortisone (low‐potency steroid) with respect to clearing or excellent improvement was downgraded by one level. In the trial by <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a>, there were more participants with DLE in the hydroxychloroquine group. This created unbalanced treatment groups, which could have influenced the outcomes of clearing or excellent improvement and more than 50% reduction in erythema (<a href="./full#CD002954-tbl-0002">summary of findings Table 2</a>). We identified no other potential sources of bias that might have had a direct effect on any risk measures presented, However, in many instances our ability to assess these was unclear. </p> <p>Sample size was judged to be inadequate in all of the included studies, except in the case of <a href="./references#CD002954-bbs2-0004" title="RoenigkHH , MartinJS , EichornP , GilliamJN . Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis; Cutaneous Medicine for the Practitioner1980;25(3):281‐5. [PUBMED: 6987043] ">Roenigk 1980</a> with 78 participants (others ranged from 10 to 58 participants per study). This resulted in imprecise measures of effect in instances where these were presented, and evidence was therefore downgraded accordingly in instances where assessment of the quality of evidence is provided (<a href="./full#CD002954-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD002954-tbl-0002">summary of findings Table 2</a>). The small numbers in <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> may weaken the validity of this study, as does the lack of a control arm, as neither intervention is of established efficacy (<a href="./full#CD002954-tbl-0002">summary of findings Table 2</a>). The inclusion of people with subacute cutaneous lupus erythematosus is an even greater source of possible error and the results require confirmation. </p> <p>We also assessed the quality of evidence for adverse events leading to discontinuation or significant morbidity in four out of five comparisons in the 'Summary of findings' tables. The quality of evidence was moderate, with downgrading for imprecision in all comparisons because the evidence was based on only one study with a small number of participants. Furthermore, only <a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> reported participants discontinuing, while the remaining studies only reported minor adverse events. The overall sample size may not have been large enough to identify serious adverse events. </p> <p>All of the comparisons included in this review were assessed in single studies, which did not allow us to assess consistency of results across studies. As such it was not possible in our review to assess what factors could potentially contribute to differences in findings between studies (heterogeneity). </p> <p>Indirectness cannot be assessed with confidence in the included studies. As the studies were performed in specialist clinics and most people with DLE are likely to be treated initially at that level, the setting is not out of line with clinical practice. </p> </section> <section id="CD002954-sec-0100"> <h3 class="title" id="CD002954-sec-0100">Potential biases in the review process</h3> <p>We attempted to conduct a comprehensive search for studies, but the fact that one study has not yet been incorporated may be a source of potential bias (<a href="./references#CD002954-bbs2-0037" title="PothinamthongP , JanjumratsangP . A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. Journal of the Medical Association of Thailand= Chotmaihet Thangphaet2012;95(7):933‐40. [PUBMED: 22919989] ">Pothinamthong 2012</a>). Studies in which participants had SLE or undefined cutaneous LE were excluded from the review, but two studies that included participants with DLE and SCLE, (<a href="./references#CD002954-bbs2-0005" title="RuzickaT , SommerburgC , GoerzG , KindP , MensingH . Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. British Journal of Dermatology1992;127(5):513‐8. [PUBMED: 1467292] ">Ruzicka 1992</a> and <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a>), were included and this may have introduced a bias. There were 12 studies identified in trials registries, but unpublished and most without contact details. The reviewers were unable to establish the outcome of these trials. After the publication of the original protocol and review (<a href="./references#CD002954-bbs2-0090" title="JessopS , WhitelawD , JordaanF . Drugs for discoid lupus erythematosus. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD002954] ">Jessop 2000</a>), a scoring measure was published, and has been widely used for reporting outcomes in DLE (<a href="./references#CD002954-bbs2-0039" title="AlbrechtJ , TaylorL , BerlinJA , DulayS , AngG , FakharzadehS , et al. The CLASI (Cutaneous Lupus Erythematosus disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. Journal of Investigative Dermatology2005;125(5):889‐94. [PUBMED: 16297185] ">Albrecht 2005</a>). One included study (<a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a>) reported outcomes using this scoring measure, but the data were not included in our systematic review because this type of outcome measure was not specified in the review protocol. </p> </section> <section id="CD002954-sec-0101"> <h3 class="title" id="CD002954-sec-0101">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other relevant reviews or studies.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002954-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/urn:x-wiley:14651858:media:CD002954:CD002954-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_t/tCD002954-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD002954-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002954-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/urn:x-wiley:14651858:media:CD002954:CD002954-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_t/tCD002954-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002954-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002954-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/urn:x-wiley:14651858:media:CD002954:CD002954-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_t/tCD002954-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluocinonide versus hydrocortisone cream, Outcome 1 Resolution of skin lesions." data-id="CD002954-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fluocinonide versus hydrocortisone cream, Outcome 1 Resolution of skin lesions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#CD002954-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002954-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/urn:x-wiley:14651858:media:CD002954:CD002954-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_t/tCD002954-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acitretin versus hydroxychloroquine, Outcome 1 Resolution of skin lesions." data-id="CD002954-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Acitretin versus hydroxychloroquine, Outcome 1 Resolution of skin lesions.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#CD002954-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002954-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/urn:x-wiley:14651858:media:CD002954:CD002954-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_t/tCD002954-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Acitretin versus hydroxychloroquine, Outcome 2 Clearing of erythema." data-id="CD002954-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Acitretin versus hydroxychloroquine, Outcome 2 Clearing of erythema.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#CD002954-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/media/CDSR/CD002954/image_n/nCD002954-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002954-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fluocinonide 0.05% compared with hydrocortisone 1%</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fluocinonide 0.05% compared with hydrocortisone 1% for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> not stated </p> <p><b>Intervention:</b> fluocinonide </p> <p><b>Comparison:</b> hydrocortisone </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>hydrocortisone</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>fluocinonide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> <p>(after 6 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 100</p> <p>(9 to 79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.77 (0.95 to 8.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The number of adverse events in this study was small and results were presented narratively. For hydrocortisone, 1 person developed acne and 3 experienced irritation. 2 patients who were assigned to fluocinonide experienced burning. There was no discontinuation in either group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk was the mean risk for the study population</p> <p><sup>1</sup>Downgraded by two levels due to imprecision and high risk of bias (incomplete outcome data).<br/> <sup>2</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fluocinonide 0.05% compared with hydrocortisone 1%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002954-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patients or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> specialised lupus clinic </p> <p><b>Intervention:</b> acitretin </p> <p><b>Comparison:</b> hydroxychloroquine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>hydroxychloroquine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>acitretin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> <p>(after 8 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 100</p> <p>(27 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.54 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> <p>(after 8 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 100</p> <p>(25 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61 (0.36 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Information on adverse events was presented narratively. 27 out of 28 participants receiving acitretin had at least one adverse event compared with 17 out of 30 patients treated with hydroxychloroquine. 4 people receiving acitretin discontinued treatment due to dry lips and gastrointestinal symptoms. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk was the mean risk for the study population.</p> <p><sup>1</sup>Downgraded by two levels due to imprecision and high risk of bias (non‐comparable treatment arms).<br/> <sup>2</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002954-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1%</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1% for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patients or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> dermatology clinics </p> <p><b>Intervention:</b> pimecrolimus </p> <p><b>Comparison:</b> betamethasone </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> <p>(after 8 weeks of treatment)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a statistically significant reduction in the disease severity score in both treatment groups; however, clearing or improvement was not presented as a percentage and no comparative analyses were performed. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002954-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">R‐salbutamol 0.5% topical cream compared with placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>R‐salbutamol 0.5% topical cream compared with placebo for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> dermatology departments </p> <p><b>Intervention:</b> R‐salbutamol </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>While data on overall improvement were provided in the study, the number of participants with complete resolution in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> could not be obtained from the trial report. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>While data on erythema were provided in the study report, the number of participants with at least 50% reduction in erythema in <a href="./references#CD002954-bbs2-0002" title="JemecGB , UllmanS , GoodfieldM , BygumA , OlesenAB , Berth‐JonesJ , et al. A randomized controlled trial of R‐salbutamol for topical treatment of discoid lupus erythematosus. British Journal of Dermatology2009;161(6):1365‐70. [PUBMED: 19681862] ">Jemec 2009</a> could not be obtained from the trial report. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not assessed.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results for adverse events were presented narratively. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by 9 participants). None of the adverse events were considered serious. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">R‐salbutamol 0.5% topical cream compared with placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002954-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tacrolimus 0.1% cream compared with placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Tacrolimus 0.1% cream compared with placebo for discoid lupus erythematosus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> people with discoid lupus erythematosus </p> <p><b>Settings:</b> dermatology departments </p> <p><b>Intervention:</b> tacrolimus </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Illustrative comparative risks (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clearing or excellent improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants with DLE in either group in the study by <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> experienced complete clearing. Unable to GRADE due to 0 events in both groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 50% reduction in erythema</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results for erythema in the study by <a href="./references#CD002954-bbs2-0003" title="KuhnA , GenschK , HaustM , SchneiderSW , BonsmannG , Gaebelein‐WissingN , et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double‐blind, vehicle‐controlled trial. Journal of the American Academy of Dermatology2011;65(1):54‐64. [PUBMED: 21501887] ">Kuhn 2011</a> were not reported separately. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life measure</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events of medication, leading to discontinuation or significant morbidity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Results for adverse events were presented narratively. In the tacrolimus group, 5 participants complained of slight burning and itching, and in 1 person a herpes simplex infection was reactivated. There were no serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Tacrolimus 0.1% cream compared with placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/full#CD002954-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002954-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluocinonide versus hydrocortisone cream</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Resolution of skin lesions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluocinonide versus hydrocortisone cream</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#CD002954-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002954-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acitretin versus hydroxychloroquine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Resolution of skin lesions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clearing of erythema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Acitretin versus hydroxychloroquine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002954.pub3/references#CD002954-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002954.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002954-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002954-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD002954-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD002954-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002954-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD002954-note-0001">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002954-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002954\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002954\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002954\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002954\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002954\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002954.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002954.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002954.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002954.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002954.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728162996"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002954.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728163000"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002954.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebdc41c2df498',t:'MTc0MDcyODE2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 